170 related articles for article (PubMed ID: 37698206)
1. Is Treosulfan-Based Conditioning Attractive as a Reduced-Intensity Conditioning Regimen in Korea?
Kim SH; Ji YS; Yun J; Choi SH; Lim SH; Kim CK; Park SK
J Korean Med Sci; 2023 Sep; 38(36):e281. PubMed ID: 37698206
[TBL] [Abstract][Full Text] [Related]
2. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.
Cseh A; Galimard JE; de la Fuente J; Isgro A; Zecca M; Garwer B; Biffi A; Aljurf M; Sundin M; Belendez C; Locatelli F; Balduzzi A; Lawson S; Sengeloev H; Ifversen M; Saccardi R; Wynn R; Lankester AC; Corbacioglu S; Peters C
Br J Haematol; 2024 Jan; 204(1):e1-e5. PubMed ID: 37795523
[TBL] [Abstract][Full Text] [Related]
3. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
[TBL] [Abstract][Full Text] [Related]
4. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
5. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kimura T; Kanda J; Fukuda T; Atsuta Y; Ishiyama K
Transplant Cell Ther; 2022 Jun; 28(6):323.e1-323.e9. PubMed ID: 35296446
[TBL] [Abstract][Full Text] [Related]
6. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
7. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
9. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
[TBL] [Abstract][Full Text] [Related]
10. Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
O'Hagan Henderson S; Frietsch JJ; Hilgendorf I; Hochhaus A; Köhne CH; Casper J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2599-2609. PubMed ID: 34674031
[TBL] [Abstract][Full Text] [Related]
11. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine melphalan versus fludarabine treosulfan for reduced intensity conditioning regimen in allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Chichra A; Nayak L; Kothari R; Kalantri S; Bonda A; Gokarn A; Punatar S; Mirgh S; Jindal N; Bagal B; Kannan S; Mathew L; Khattry N
Int J Hematol; 2024 Jan; 119(1):71-79. PubMed ID: 37952243
[TBL] [Abstract][Full Text] [Related]
13. Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
Berning P; Kolloch L; Reicherts C; Call S; Marx J; Floeth M; Esseling E; Ronnacker J; Albring J; Schliemann C; Lenz G; Stelljes M
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38702400
[TBL] [Abstract][Full Text] [Related]
14. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
15. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
Sheth V; Labopin M; Canaani J; Volin L; Brecht A; Ganser A; Mayer J; Labussière-Wallet H; Bittenbring J; Shouval R; Savani B; Mohty M; Nagler A
Bone Marrow Transplant; 2019 Apr; 54(4):531-539. PubMed ID: 30087463
[TBL] [Abstract][Full Text] [Related]
16. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
17. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Alatrash G; Saberian C; Bassett R; Thall PF; Ledesma C; Lu Y; Daher M; Valdez BC; Kawedia J; Popat U; Mehta R; Oran B; Nieto Y; Olson A; Anderlini P; Marin D; Hosing C; Alousi AM; Shpall EJ; Rondon G; Chen J; Qazilbash M; Champlin RE; Kebriaei P
Transplant Cell Ther; 2022 Aug; 28(8):501.e1-501.e7. PubMed ID: 35618218
[TBL] [Abstract][Full Text] [Related]
18. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation.
Ussowicz M
Drugs Today (Barc); 2020 Jun; 56(6):389-403. PubMed ID: 32525137
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]